Floatz logo

HUMANIZED, DUAL-AFFINITY RE-TARGETING, OR (DART), MOLECULE THAT RECOGNIZES BOTH CD123 AND CD3

Interleukin-3 Receptor Subunit Alpha Positive

City of Hope Medical Centermonoclonal_antibodyPhase 2Dormant
CCC
49/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
34/ 100
Competitive Position
95/ 100

Competitive context

4 Active assets in the Interleukin-3 Receptor Subunit Alpha Positive cohort.

Asset / SponsorPhaseRating
Autologous Cd123Car-Cd28-Cd3Zeta-Egfrt-Expressing T Lymphocytes
City of Hope Medical Center
Phase 1CC
Allogeneic Cd123Car-Cd28-Cd3Zeta-Egfrt-Expressing T-Lymphocytes
City of Hope Medical Center
Phase 1CC
Cyclophosphamide
City of Hope Medical Center
Phase 1CC
Fludarabine
City of Hope Medical Center
Phase 1CC

Same molecule, other indications

HUMANIZED, DUAL-AFFINITY RE-TARGETING, OR (DART), MOLECULE THAT RECOGNIZES BOTH CD123 AND CD3 is also rated in:

acute myeloid leukemiaDormant
CCC
Indicative ·
54 / 100
View asset →
chronic myeloid leukemiaDormant
CCC
Indicative ·
53 / 100
View asset →
hairy cell leukemiaDormant
CCC
Indicative ·
53 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →